ECT Chairman available for Q&A, page-66

Hi Sam,
Apologies, I did miss your question. Not intentionally though.

We have all learnt a lot from the NMDC experience. We certainly have a more calculated set of rules in how we approach any new negotiations but its really difficult to outline these because it would be akin to explaining one's tactics ahead of a poker match.

What I would say is that, we have progressed many elements of the commercialisation of both Coldry and Matmor and our fundamental knowledge on these processes that I am not concerned with arguing the case for more value to ECT in any future JV.

The process of being interrogated at a fundamental engineering and chemistry level to justify the basis for our tech's efficacy has only made us more capable to have that conversation again with the benefit of even more R&D to support those notions.

Future negotiations will certainly take a more purposeful and pragmatic tone and be less about preserving cultural sensitivity at the expense of commercial pragmatism.

Regards
Glenn